Yes — but the answer reveals more about pharmaceutical economics than safety science.

Peptides are not experimental compounds. They are the original therapeutics of modern medicine. Insulin, introduced in 1921, is a peptide. So are oxytocin, vasopressin, ACTH, growth hormone, and glucagon. Modern GLP-1 drugs — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), liraglutide (Saxenda) — are peptides. SS-31 received FDA accelerated approval in September 2025 as the first mitochondrial therapy. All of endocrine physiology — and much of immunology, metabolism, and tissue repair — is peptide-driven. These molecules are not fringe; they are the vocabulary biology uses to coordinate systems.

The past decade has expanded this domain. Peptides that support microvascular repair, immune recalibration, mitochondrial stability, and metabolic control have become subjects of serious academic investigation. Their mechanisms are clear, their activity is physiologic, and their potential spans orthopedics, gastroenterology, neurology, immunology, and metabolism.

Against this backdrop, the FDA's 2023 decision to restrict dozens of peptides appears, at first glance, inexplicable. No adverse-event clusters had emerged. No new toxicology data had surfaced. Several of the banned compounds were under active examination at major research institutions. And yet they were designated "significant safety concerns" and effectively removed from clinical use.

Understanding that decision — and what it implies — requires stepping back from the molecules themselves. The peptide story exposes a deeper issue: a structural mismatch between the biological realities of human repair and the regulatory-economic architecture that governs pharmaceuticals.

Peptides: A Brief History Grounded in Physiology

Peptides entered medicine long before small-molecule pharmacology matured. Insulin transformed metabolic disease. Oxytocin and vasopressin shaped obstetrics and cardiovascular medicine. ACTH and growth hormone clarified the relationship between stress, growth, and endocrine reserve. These therapies worked because they echoed internal signalling — short, modular instructions that tissues already knew how to interpret.

Modern metabolic drugs — GLP-1 (glucagon-like peptide-1) analogues — continue this pattern. Their mechanism is explicitly physiologic: GLP-1 amplifies satiety signalling and moderates glucose kinetics. The success of these drugs is not despite their peptide nature, but because of it.

The same logic underlies newer domains of peptide research — academic centers have explored peptides in areas where traditional pharmacology struggles:

• Case Western: ISP peptide promoting recovery after spinal cord injury¹
• Johns Hopkins: Novel peptide therapy blocking AMPKαS496 phosphorylation to improve mitochondrial dynamics in obesity and aging²
• Yale: Metabolic-immune crosstalk — the systems biology that peptide research increasingly engages with³

These are not fringe institutions. They represent the center of American biomedical science. Their interest in peptides reflects a simple reality: the mechanisms make sense.

Why Peptides Aren't More Widely Prescribed

The FDA's regulatory framework was built for an earlier pharmacologic era — one defined by synthetic small molecules, single-target mechanisms, and linear disease categories. Drugs were expected to act on a narrow receptor, produce a measurable change in an isolated endpoint, and fit neatly into a proprietary commercial model.

The Clinical Trial Problem

Randomized Controlled Trials (RCTs) are one of medicine's most powerful tools — when the biological problem is discrete: tumors, bacterial infections, acute psychosis, GLP-1 monotherapy outcomes (weight, A1c, liver fat), etc.

In these cases, the target is clear, the pathway is narrow, and a single molecule can carry the therapeutic load. RCTs excel in this paradigm, and have led to major advances in medicine and care — improving or extending the lives of millions of patients.

Monotherapy RCTs deliberately remove all contextual layers — diet, sleep, immune tone, and most critically, other interventions — in order to isolate the efficacy of a drug or single-company multi-drug interventions. That is appropriate for discrete diseases; it is a category error for system biology. A compound that works best as part of a broader protocol will fail a trial designed to test it in isolation — not because it doesn't work, but because the trial is asking the wrong question. (The AOD-9604 case study illustrates this exactly: clean safety data, clear mechanism, but "failed" as an obesity monotherapy because a lipolytic peptide fragment was never going to replace diet, exercise, and metabolic context.)

In economic terms, the FDA requires Phase I, II, and III trials for approval — typically costing $1–2 billion in total. Patentable small molecules can justify that investment. Natural peptides cannot — and without FDA approval, physicians have no standard prescribing pathway.

What Makes Peptides Different From Conventional Drugs

Biological systems, such as metabolic health, do not behave like single-target diseases. They adapt, compensate, integrate, and coordinate across tissues. Peptides reflect this reality — they tend to:

• Act across systems rather than single pathways
• Restore function instead of suppressing symptoms
• Degrade into amino acids rather than persisting as foreign chemistry
• And most critically, cannot be patented in their natural form

This last point is decisive. Modern pharmaceutical development depends on exclusivity — a period during which a company can recoup the cost of large clinical trials through protected revenue. Natural peptides offer no such protection. They are inexpensive to produce, physiologic in action, and often reduce the need for long-term pharmacotherapy.

These properties make peptides biologically powerful but commercially inconvenient — and ill-suited for the FDA's regulatory framework. They also make them difficult to evaluate using tools built for a different pharmacologic era.

A regulatory system funded in part by industry fees and structured around proprietary chemistry is therefore structurally disincentivized from advancing — or even accommodating — these molecules. It is not a matter of intent. It is a matter of architecture.

The 2023 Peptide Ban: A Structural Outcome, Not a Scientific One

In this context, the FDA's 2023 reclassification becomes clearer. Dozens of peptides — including BPC-157, TB-500 (Thymosin Beta-4), Semax, Selank, MOTS-c, Thymosin Alpha-1, and others — were designated "significant safety concerns" and rendered ineligible for compounding. Some of these compounds, like Thymosin Alpha-1, are approved in 35+ countries and have decades of clinical data. Others, like BPC-157, have no published human clinical trials — not because they failed them, but because no commercial sponsor has an economic reason to run them. The Category 2 designation did not distinguish between the two.

What changed scientifically? Nothing.

No new publicly available human toxicity findings preceded the decision. No mechanistic revelations. No accumulation of adverse events. The decision did not map to published evidence.

It mapped to incentives.

The restricted peptides were those that had become widely used, clinically versatile, physiologically coherent, and increasingly visible to the public — precisely the characteristics that conflict with a chronic-care pharmaceutical model. Their growth through compounding pharmacies further bypassed the proprietary delivery channels on which major drug revenues depend.

This is not a matter of intent — it is a matter of architecture. And in that architecture, the decision is structurally predictable. The molecules most aligned with human biology are the least aligned with the economic substrate of modern drug regulation.

This is separate from the legitimate question of compounding pharmacy quality control — contamination, potency inconsistencies, and sterility failures are real concerns. But those are manufacturing oversight problems, not indictments of the molecules themselves. The FDA's Category 2 designation did not distinguish between the two.

The Regulatory Double Standard

The paradox becomes sharper when contrasted with the regulatory treatment of high-risk synthetic drugs. Over the past several decades, the FDA has approved — and often defended — medications later shown to have catastrophic safety profiles: Vioxx, with tens of thousands of cardiovascular deaths; Fen-Phen, causing irreversible valvular damage; Rezulin, withdrawn for hepatic failure; OxyContin, which precipitated a national epidemic; atypical antipsychotics, associated with profound metabolic deterioration; SSRIs (selective serotonin reuptake inhibitors), approved on 6–8 week trials and prescribed for years — with independent analysis later revealing that 33 of 36 negative trials were either unpublished or reframed as positive⁸, and meta-analysis showing the drugs barely outperformed placebos on standardized scales⁹.

These drugs fit the FDA's structural model. They were proprietary, patent-protected, and developed within the familiar economic architecture.

Peptides, in contrast, do not fit that architecture — and were restricted despite clean safety histories for those studied in clinical settings. To an uninvolved observer, the asymmetry appears illogical. Within the system's incentive structure, it is entirely consistent.

Long COVID: The Irony Made Concrete

Long COVID presented exactly the kind of problem that peptide and systems biology are built to address: NAD⁺ depletion, mitochondrial dysfunction, immune dysregulation, gut barrier breakdown, and autonomic instability — all at once, in the same patient. These are not random findings; they are signatures of systemic collapse, and they map directly onto the mechanisms that restricted peptides target.

Leading institutions saw this and acted:

• Mass General Brigham (Harvard): Ran a randomized NR (nicotinamide riboside) trial in 58 Long COVID patients (NCT04809974)⁴. NAD⁺ levels increased 2.6–3.1 fold. Within-group analyses showed improvements in fatigue, sleep, and executive function by 10 weeks. A separate pilot combined low-dose naltrexone with NAD⁺ (NCT05430152)⁵ and found significant quality-of-life improvements.
• University of Rome "Tor Vergata": Studied Thymosin Alpha-1 in post-acute COVID patients and found it restored depleted T-cell populations — the immune exhaustion pattern that defines persistent post-viral illness.
• Yale School of Medicine: Tested VIP (vasoactive intestinal peptide) in Phase 2/3 acute COVID ARDS trials^6,7, with an 80-patient Phase 2 RCT showing reduced hospital stays.

The pattern is hard to miss. The same class of compounds the FDA placed on a "do not compound" list were being trialed at Harvard, Yale, and Rome — and showing results in a disease conventional medicine was struggling to treat. The scientific trajectory and the regulatory trajectory moved in opposite directions.

What's Changing: The 2026 Reclassification

On February 27, 2026, 14 of the 19 Category 2 peptides were announced for reclassification back to Category 1 — restoring their eligibility for compounding by licensed pharmacies with a physician's prescription. The affected peptides include BPC-157, Thymosin Alpha-1, Semax, Selank, MOTS-c, GHK-Cu, AOD-9604, and CJC-1295, among others.

HHS Secretary Robert F. Kennedy Jr. acknowledged directly that the restrictions "created the gray market" — which is precisely what a structural analysis would predict. Remove legitimate access to compounds with demonstrated clinical utility, and demand doesn't disappear. It moves underground.

Five peptides with weaker human safety data may remain restricted. Official reclassification is expected within weeks.

This does not make these peptides FDA-approved drugs. It restores the compounding pathway that existed before 2023. The distinction matters: FDA approval requires the billion-dollar trial investment that natural peptides cannot justify. Compounding access requires a physician's prescription and a licensed pharmacy. These are different regulatory categories, and conflating them obscures the actual landscape.

Separately, NAD⁺ precursors have seen their own regulatory shift. NMN (nicotinamide mononucleotide) was reinstated as a lawful dietary supplement in September 2025 after the FDA reversed a 2022 exclusion. NR (nicotinamide riboside) holds GRAS status and remains available without prescription.

A System Misaligned With Biology

Peptides are the internal language of physiology. They regulate growth, repair, metabolism, immune tone, and vascular stability. They restore function, reduce chronic drug dependence, and lack the intellectual property structure required to justify large trials. Those studied through clinical research have clean safety profiles, clear mechanisms, and active academic engagement. Yet they have been restricted due to regulatory frameworks, economic incentives, and a trial paradigm misaligned with system biology.

In a system optimized for long-term prescription revenue and proprietary chemistry, these properties become liabilities. Said differently, peptides were restricted not because they are unsafe, but because they are incompatible with the regulatory and economic model that governs modern pharmaceuticals.

COVID and Long COVID revealed the cost of this misalignment. When faced with immune-metabolic collapse — a domain where peptide and NAD⁺ biology offer coherent mechanistic interventions — the medical system defaulted to fragmentation and symptomatic treatment. Academic centers adjusted. Regulation did not.

The peptide paradox is therefore not about individual molecules. It is a diagnostic of a broader problem: biology has evolved, evidence has advanced, but regulation remains anchored to an older understanding of human biology and economic logic. Until those systems realign, the therapies most capable of restoring physiology will remain the least accessible — not because they pose risk, but because they challenge a model built to manage, rather than resolve, chronic disease.

Frequently Asked Questions

References

¹ Lang BT et al., "Modulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury," Nature 518, 404–408 (2015) — PMID: 25470046 — https://case.edu/medicine/about/newsroom/our-latest-news/peptide-shows-great-promise-treating-spinal-cord-injury
² Pearah A et al., "Blocking AMPKαS496 phosphorylation improves mitochondrial dynamics and hyperglycemia in aging and obesity," Cell Chemical Biology 30(12), 1585–1600 (2023) — PMID: 37890479 — https://www.hopkinsmedicine.org/news/newsroom/news-releases/2023/11/novel-peptide-therapy-shows-promise-for-treating-obesity-diabetes-and-aging
³ Tannahill GM et al., "Succinate is an inflammatory signal that induces IL-1β through HIF-1α," Cell Reports (2018) — https://www.cell.com/cell-reports/fulltext/S2211-1247(18)31069-6
⁴ Mass General Brigham NR Trial (NCT04809974) — https://clinicaltrials.gov/study/NCT04809974
⁵ LDN + NAD⁺ Trial (NCT04604704) — https://clinicaltrials.gov/study/NCT04604704
⁶ Yale VIP Exploratory Protocols — https://medicine.yale.edu/research/recover/
⁷ VIP/Aviptadil Acute COVID Trials — https://clinicaltrials.gov/search?term=aviptadil
⁸ Turner EH et al., "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy," NEJM (2008); cited in Angell M, "Drug Companies & Doctors: A Story of Corruption," New York Review of Books (2009) — https://www.nybooks.com/articles/2009/01/15/drug-companies-doctorsa-story-of-corruption/
⁹ Kirsch I et al., "The Emperor's New Drugs: An Analysis of Antidepressant Medication Data Submitted to the US FDA," PLoS Medicine (2008) — PMID: 18364348 — https://pubmed.ncbi.nlm.nih.gov/18364348/

Educational content only. These peptides are not FDA-approved — not because of safety concerns, but because natural peptides cannot be patented, making the billion-dollar clinical trial pathway economically nonviable for any commercial sponsor. This is a structural reality of pharmaceutical economics, not a reflection of safety or efficacy. Work with a qualified healthcare provider before using any peptide protocol.